Skip to main content

Quest Patient Service Centers will be closed on Thursday, November 26th and will close at 12:00 PM on Friday, November 27th in observance of Thanksgiving and to give our frontline team time to recharge. Don’t let the holiday interrupt your care. Plan your visit today.

Hide

  

Introduction

Get to know Dr Racke

Hear from Dr Racke about his role at Quest, his prior experience, and more.

FAQ: Learn more about Dr Racke

Dr. Racke: Neurology has always fascinated me because the brain continually adapts to the world around us. Likewise, the immune system is highly dynamic and responsive to external influences. Neuroimmunology sits at the intersection of these 2 complex systems, which made it an especially compelling field for me. I was drawn to multiple sclerosis specifically because, unlike many neurological disorders at the time, it primarily affected young adults. As a young physician, I could relate to those patients and appreciated the opportunity to help people whose lives were still ahead of them. That remains one of the most rewarding aspects of my career.

Dr. Racke: Fifty years ago, there was a common saying in neurology: "Diagnose and adios." We could identify neurological diseases, but we had very few effective treatments. When I began my fellowship in multiple sclerosis, there were no approved disease-modifying therapies. Today, there are more than 20 treatment options. Likewise, spinal muscular atrophy has proven responsive to gene-based therapies that have transformed a once fatal childhood disease into one where many patients now survive and thrive into adolescence and adulthood.

Now, research on Alzheimer's disease, the most common cause of dementia – accounting for roughly 60–80% of cases – enters a pivotal stage, much as multiple sclerosis did 3 decades ago. Our understanding of the biology is advancing rapidly, disease-modifying therapies are beginning to emerge, and new blood-based biomarkers are allowing us to identify patients earlier than ever before. The progress we've made across neurology gives me great confidence that the most significant breakthroughs are still ahead.

Dr. Racke: Two things come to mind.

First, continued progress depends on sustained investment in research. Neurological diseases require long-term studies, and interruptions in funding can delay discoveries and slow the development of new therapies.

Second, despite remarkable advances, we still don't fully understand many of the mechanisms driving neurological disease. Multiple sclerosis is a good example. We can now control inflammation remarkably well, preventing relapses and new lesions in many patients. Yet some continue to experience neurodegeneration and disability progression despite effective treatment. That tells us there are important disease processes we have yet to understand. 

Dr. Racke: Biomarkers have long been important in neurology. In multiple sclerosis, for example, oligoclonal bands have been a cornerstone of diagnosis for more than 70 years, providing early evidence of how useful biomarkers can be. But their clinical role has expanded in recent years as our understanding has deepened.

More recently, we have added to the toolbox of blood-based biomarkers that reflect disease activity, tissue injury, and treatment response in real time. However, we know that markers are not entirely disease-specific. Both neurofilament light chain (NfL), a marker of neuronal and axonal injury, and glial fibrillary acidic protein (GFAP), a marker of astrocytic activation and gliosis, are elevated in patients with multiple sclerosis and Alzheimer's disease. Similarly, phosphorylated tau biomarkers are widely used in Alzheimer's disease diagnoses but p-tau181 can also be elevated in ALS patients and p-tau217 rises with frontotemporal dementia and following cerebrovascular injury.

So, while the field has proven highly complex, we’re learning. And more and more often, we’re able to successfully use blood-based biomarkers for risk stratification, treatment selection, and disease monitoring.

Dr. Racke: Traditional diagnostic imaging tools remain important in neurology but are limited by high cost and inaccessibility, especially as demand for earlier diagnosis grows.

By the time cognitive symptoms become apparent in Alzheimer's disease, amyloid pathology may have been accumulating in the brain for 15 to 20 years. Historically, confirming the presence of amyloid required costly PET imaging or invasive cerebrospinal fluid analysis. However, imaging has limitations when it comes to detecting early biological changes. MRI detects hippocampal and cortical atrophy, but these changes tend to appear relatively late in the disease process. Amyloid PET can detect amyloid accumulation years before symptoms but is unable to determine the rate of decline. And, of course, PET involves radiation exposure, which makes it difficult to use for large-scale screening or repeated monitoring.

Dr. Racke: Blood-based biomarkers have several advantages starting with the fact that they are minimally invasive, requiring only a simple blood draw, which makes them highly scalable and accessible. This ease of testing means that measurements can be taken repeatedly and relatively inexpensively, so clinicians and researchers can monitor progression or treatment response in near real-time. Also, many biomarkers—p-tau, NfL and GFAP—can reflect underlying neurodegeneration, axonal injury, or glial activation before major structural changes appear on MRI scans, assisting in early detection.

In these ways, biomarkers help identify individuals with evidence of underlying pathology earlier and more efficiently, which may support clinical decision-making and clinical trial enrollment.

Dr. Racke: Broad adoption of blood-based biomarkers will depend on establishing clear clinical utility across different care settings and patient population. The same biomarker result may mean different things to different patients, depending on the patient's age, symptoms, risk factors, and overall clinical context. For example, blood-based biomarkers for Alzheimer's disease tend to have a higher positive predictive value when ordered by memory specialists than when used in more general clinical settings. This is because a memory specialist is seeing patients who've already been evaluated in some way, and they already know something isn't right.

As evidence continues to accumulate in trials like TRAILBLAZER-ALZ 3 that are testing earlier intervention strategies, we will learn how to apply biomarkers across patient populations for a more precise, biology-driven approach to diagnosis and patient management.

Dr. Racke: Many of the earliest Alzheimer's disease clinical trials were conducted before we had reliable methods to confirm underlying Alzheimer's pathology. As a result, some studies likely enrolled patients with other causes of cognitive impairment, making it more difficult to demonstrate a treatment effect.

Today, blood-based biomarkers join cerebrospinal fluid analysis and imaging to allow us to identify patients with greater diagnostic certainty in appropriate clinical settings. Multiple sclerosis is a good example. When highly effective therapies suppress inflammatory disease activity, biomarkers such as NfL often return toward normal, providing objective evidence that injury has been reduced.

So, investigators can use biomarkers to enrich clinical trials with participants who are most likely to benefit from the therapy being studied, reducing patient heterogeneity, potentially reducing screen failures, and increasing confidence that trial outcomes truly reflect the effects of the intervention.

Dr. Racke: In my view, absolutely. Just a few years ago, Alzheimer's disease diagnosis largely depended on the presence of cognitive symptoms with confirmatory testing such as amyloid PET imaging or cerebrospinal fluid analysis. Today, the field recognizes that blood-based biomarkers are an important tool for understanding the disease.

Neurologist Dr. Richard S. Isaacson, a pioneer in Alzheimer's prevention research, promotes using biomarker testing combined with genetic risk, lifestyle factors, and other clinical information to guide personalized prevention strategies. He contends that the tangible evidence of risk provided in this testing helps to motivate the adoption of healthy behaviors such as regular physical activity, dietary improvements, and better management of cardiovascular risk factors.

Still, clinical guidelines remain appropriately more conservative in approach. Most professional societies recommend biomarker testing only when the results will meaningfully influence diagnosis or treatment decisions, rather than for routine screening of asymptomatic individuals. Once biomarkers identify patients for whom there is a clear therapeutic intervention, their role in clinical practice will naturally expand.

Dr. Racke: No laboratory test can be interpreted independently of the clinical context. Equally important to a test's sensitivity and specificity, are pretest probability and disease prevalence, because those factors determine the positive and negative predictive value of the result. This is particularly relevant in Alzheimer's disease. The Global CEO Initiative on Alzheimer's Disease has proposed performance standards for blood-based biomarkers intended for use as either triage or confirmatory tests. Those recommendations assume that the test is being applied to an appropriate patient population for whom the test yields approximately 90% sensitivity and specificity.

However, if you screen healthy college students with a blood test designed to detect sporadic, late-onset Alzheimer's disease, almost every result would be negative—not because the test is faulty, but because the disease biology the test is designed to detect simply is not present. Additionally, these biomarkers are optimized for late-onset Alzheimer's disease and may be less informative in patients with early-onset Alzheimer's disease. For them, genetic testing can be more appropriate. 

Dr. Racke: Successfully implementing blood-based biomarker testing across multi-site clinical trials requires analytical standardization, operational consistency, and the ability to generate reproducible results regardless of where a patient's sample is collected or analyzed.

Regulatory clearance is also a factor in ensuring inter-laboratory agreement of biomarker interpretation so that investigators and sponsors can have confidence that biomarker results mean the same thing regardless of where the testing is performed.

Equally important are laboratory quality systems and operational scalability. Standardized specimen collection, handling, transportation, quality control, and reporting all contribute to minimizing variability across study sites. Large reference laboratories have demonstrated that it is possible to perform these assays with rapid turnaround times and consistent quality across broad geographic regions.

Dr. Racke: First, I believe biomarkers will not simply enable earlier diagnosis but also allow us to identify disease before irreversible neurological injury has occurred and to intervene when treatments are most likely to have a meaningful impact. Second, I believe biomarkers have the potential to make neurological care more accessible and cost-effective. Today, patients with conditions such as multiple sclerosis often undergo serial MRI examinations to monitor disease activity. In the future, validated blood-based biomarkers may offer a more accessible and affordable way to monitor the disease. 

Dr. Racke: I think decentralized clinical trials have the potential to fundamentally improve both recruitment and retention, particularly in neurology, where many patients face significant barriers to participating in research.

We recently completed a high-quality biomarker study in which participants were enrolled remotely through the ICON MS portal and completed much of the study from home. Most participants had blood samples collected at Quest Patient Service Centers, while those who were unable to travel were supported through an at-home mobile phlebotomy service.

By reducing the need for repeated travel to academic medical centers, we can make research participation more convenient, improve retention, and expand access for patients who might otherwise be excluded because of geography, mobility limitations, work schedules, or caregiving responsibilities. The decentralized approach also supports the enrollment of more real-world patient populations inclusive of individuals from rural communities, medically underserved areas, and practices that may not have direct access to specialized research infrastructure.

Dr. Racke: We recognize that neurodegeneration is rarely driven by a single pathological process. Large autopsy studies have shown overlapping conditions—for example, Alzheimer’s pathology coexisting with Lewy body disease. This has important implications for biomarker development. If we only measure a single pathway, we risk oversimplifying the biology and potentially underestimating the drivers of disease in a given patient. The future will likely involve multi-analyte biomarker panels that can simultaneously capture amyloid, tau, synuclein, and other neurodegenerative processes, allowing for more precise biological classification. That shift toward biologically informed, multi-pathway profiling is, I think, one of the most important frontiers in neurodegenerative disease research today.

Dr. Racke: I’d make precision diagnostics faster, more accessible, and more affordable.

Genomic sequencing and MRI imaging are perfect examples of our evolving diagnostic capabilities. Today, sequencing is used to diagnose rare genetic disease from a simple blood or saliva sample and to identify bacterial, viral, fungal, or parasitic DNA causing infectious disease faster than microscopy and culture methods. Likewise, the standard of care in academic centers has risen from standard MRI to a system that's three times more sensitive. The technology researchers exploring neurodegenerative diseases are using now is seven times better than MRI.

As impressive as these advances are, genetic testing and MRI imaging are not universally available and come at a high cost. A great opportunity lies in adding biomarkers to our toolbox with the goal of improving diagnostic efficiency to achieve a diagnosis of neurological diseases and tailor treatment to the biology of each individual patient.

Dr. Racke: Every major medical advance rests on decades of sustained investment in basic science, translational research, and carefully conducted clinical trials. One of my favorite examples of the impact of sustained research investment comes from cystic fibrosis. Former NFL quarterback, Boomer Esiason, founded the Boomer Esiason Foundation after his infant son, Gunnar, was diagnosed with cystic fibrosis. For decades, the foundation has supported research, patient care, education, and advocacy while helping to accelerate progress across the cystic fibrosis community. In 2019, Gunnar participated in clinical research of CFTR modulator therapies, which dramatically improved his lung function, overall health, and quality of life. Today, he has built a career, married, and become a father—milestones that would have been extraordinarily uncommon for many people born with cystic fibrosis just a generation ago.

I believe the same trajectory is possible across many neurological diseases. We now understand disease biology at a level that was previously unimaginable, and we have unprecedented tools to translate that knowledge into therapies. If we continue to invest in research and innovation, I am confident that the next decade will bring advances that are even more transformative than those we've already witnessed.

Dr. Racke: When I look back at my career, the transformation has been extraordinary. Many neurological diseases that were once considered untreatable now have effective therapies. At the same time, we have more powerful scientific tools than ever before to pursue treatments that remain elusive.

Duchenne muscular dystrophy is a remarkable example of how far we've come. Historically, diagnosis required an invasive muscle biopsy, and treatment options were limited primarily to supportive care and corticosteroids, which could slow disease progression but did not address the underlying cause. Today, genomic sequencing allows us to identify the specific mutation responsible for the disease, enabling precision therapies tailored to an individual patient's genetics.

We're seeing similar advances across neurology—from multiple sclerosis and spinal muscular atrophy to Alzheimer's disease and many rare neurological disorders. Blood-based biomarkers, advanced imaging, genomics, and gene-based therapies are creating new opportunities for earlier disease detection and more individualized approaches to care.

Dr. Racke: Nearly 50 years after graduating, I still hold my university's records as the all-time leading rebounder and second all-time leading scorer in basketball. I continued playing basketball during my neurology residency at Emory. I remember the residency program director asking one of my teammates, "What kind of basketball player is Mike Racke?" My teammate replied, "Mike is the most fundamentally sound basketball player I've ever played with." The program director smiled and said, "That doesn't surprise me. That's exactly how he is as a neurologist."

That comment has stayed with me because it captures how I approach both medicine and life. I was fortunate to have been an athlete at a time when college sports emphasized character, teamwork, discipline, consistency, resilience, and leadership as much as winning. Those lessons have stayed with me throughout my professional life and continue to influence how I care for patients and mentor the next generation of physicians.

Read Dr Racke's article

  

Neurology article

Blood-based biomarkers: A new window into neurological disease

Are blood-based biomarkers transforming neurology? Hear Dr. Racke's thoughts on how they could offer an accessible lens for understanding disease.

 

This article is free and can be downloaded and read at your convenience.

Webinar for Alzheimer's Disease

Ask Dr Racke a Question

Curious about emerging trends in the use of neurological biomarkers? Wondering how this technology could support your clinical trial? Submit your question to Dr Racke, and he'll respond with insights based on his extensive expertise.

Responses provided within 48 hours. Your questions will be answered directly and privately. Some frequently asked questions may also be shared on this page with your permission, adding to our "Insights from Dr Racke" section.

Submit your question

Bio

Dr. Michael K. Racke is Medical Director for Neurology at Quest Diagnostics with more than three decades of leadership experience in academia and clinical practice in the field of neurology and neuroimmunology. Dr Racke’s research focuses on developing novel tests for neurologic disorders, including monitoring therapeutic responses in diseases such as multiple sclerosis. He has authored more than 200 peer-reviewed papers, book chapters, and reviews on the pathogenesis of neuroimmunological diseases. He received his Doctor of Medicine from the University of Medicine and Dentistry of New Jersey and completed a medical internship and neurology residency at Emory University School of Medicine, followed by a neuroimmunology fellowship at the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institutes of Health (NIH).